Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.repc.2022.12.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sacubitril/Valsartan and Dapagliflozin in Patients with a Failing Systemic Right Ventricle: Effects on the Arrhythmic Burden.
J Clin Med
December 2024
Adult Congenital Heart Disease and Congenital and Familial Arrhythmias Unit, Monaldi Hospital, Leonardo Bianchi Street, 80131 Naples, Italy.
: Angiotensin receptor neprilysin inhibitor (ARNI) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) are essential medications in heart failure (HF) therapy, and their potential antiarrhythmic effects have been reported. Recently, ARNI and SGLT2i use for HF in adult congenital heart disease (ACHD) has been studied. However, whether any beneficial effects may be achieved on the arrhythmic burden in the complex population of ACHD with a systemic right ventricle (sRV) is still to be determined.
View Article and Find Full Text PDFDrug-Induced Delirium Associated With Sacubitril/Valsartan in a Patient With Chronic Kidney Disease: A Case Report.
Cureus
October 2024
Internal Medicine, St Vincent Medical Center, Bridgeport, USA.
Article Synopsis
- Drug-induced neuropsychiatric symptoms, like delirium and hallucinations, are common, especially in patients with multiple health issues and taking many medications.
- Sacubitril/valsartan is a heart failure drug that helps reduce hospitalizations, particularly in patients with preserved ejection fraction (HFpEF).
- A case report details a 79-year-old male with HFpEF and end-stage kidney disease who experienced visual hallucinations after beginning treatment with sacubitril/valsartan.
Risk stratification by renal function and NYHA class in patients with hypotension initiated on sacubitril/valsartan: a retrospective cohort study from 17 centres in Japan.
Open Heart
October 2024
Cardiovascular Medicine, Toho University Graduate School of Medicine, Ota-ku, Japan.
Background: Patients with heart failure exhibiting low systolic blood pressure (SBP) have a poor prognosis. Sacubitril/valsartan reduces cardiovascular events; however, its use in patients with low SBP has not been fully examined. Therefore, in this study, we aimed to investigate the association between baseline SBP and adverse events (AEs) in patients starting sacubitril/valsartan therapy using data from a real-world registry in Japan.
View Article and Find Full Text PDFCardiac and kidney outcomes after sacubitril-valsartan therapy: recovery of cardiac function relative to kidney function decline.
Kidney Res Clin Pract
September 2024
Division of Nephrology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Article Synopsis
- Sacubitril-valsartan is shown to lower cardiovascular mortality in patients with heart failure with reduced ejection fraction (HFrEF), but its effects during acute kidney injury (AKI) are not fully understood.
- A study enrolled 512 HFrEF patients to investigate the long-term impact of sacubitril-valsartan versus valsartan on kidney and cardiac function, particularly after instances of AKI.
- Results indicated that while both treatments had patients recovering from AKI, those on sacubitril-valsartan experienced significantly better cardiac function improvement compared to valsartan users, suggesting its potential benefits even in the context of kidney issues.
Sacubitril/valsartan reduces proteinuria depending on blood pressure in patients with stage 4-5 chronic kidney disease.
Clin Exp Nephrol
December 2024
Department of Nephrology, Kasugai Municipal Hospital, Takakicho 1-1-1, Kasugai, Aichi Prefecture, Japan.
Article Synopsis
- Blood pressure management is crucial for patients with chronic kidney disease (CKD), and recent studies highlight that many still struggle with this, even with medication.
- The study analyzed the effects of sacubitril/valsartan (ARNI) on proteinuria and blood pressure in stage 4-5 CKD patients, revealing a significant reduction in protein levels and systolic blood pressure after using ARNI for six months.
- The findings suggest that ARNI may be beneficial for reducing proteinuria in advanced CKD, especially in patients who have uncontrolled hypertension.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!